Mir-150 for the treatment of blood disorders

Abstract

The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.

1 . A method of treating thrombocytopenia in a host in need thereof, the method comprising administering an effective amount of an agent that increases miR-150 expression in a cell to a host. 
     
     
         2 . The method of  claim 1 , wherein the cell is a progenitor cell. 
     
     
         3 . The method of  claim 2 , wherein the progenitor cell is a hematopoietic progenitor cell. 
     
     
         4 . The method of  claim 1 , wherein the agent is a vector comprising a nucleic acid sequence that is at least 90% identical to SEQ. ID. No. 1. 
     
     
         5 . The method of  claim 4 , wherein the vector is a virus. 
     
     
         6 . The method of  claim 1 , wherein the agent is a nucleic acid sequence that is at least 90% identical to SEQ. ID. No. 1. 
     
     
         7 . A method of treating thrombocytopenia in a host in need thereof, the method comprising:
 a. obtaining a sample of hematopoietic progenitor cells from said host;   b. contacting the hematopoietic progenitor cells with a vector comprising a nucleic acid sequence that is at least 90% identical to SEQ. ID. No. 1; and   c. introducing the cell from step b into the host.   
     
     
         8 . A method of treating anemia in a host in need thereof, the method comprising administering an effective amount of an agent that inhibits miR-150 in a cell to a host. 
     
     
         9 . The method of  claim 8 , wherein the cell is a progenitor cell. 
     
     
         10 . The method of  claim 9 , wherein the progenitor cell is a hematopoietic progenitor cell. 
     
     
         11 . The method of  claim 8 , wherein the agent is a vector comprising a nucleic acid sequence that is at least 90% identical to SEQ. ID. No. 3. 
     
     
         12 . The method of  claim 8 , wherein the agent is an antagomir of miR-150, an anti-miR-150 oligonucleotide, an antisense oligonucleotide to miR-150 or a locked nucleic acid that anneals to miR-150. 
     
     
         13 . A method of  claim 11 , wherein the vector is a virus. 
     
     
         14 . A method of treating anemia in a host in need thereof, the method comprising:
 a. obtaining a sample of hematopoietic progenitor cells from said host;   b. contacting the hematopoietic progenitor cells with a vector comprising a nucleic acid sequence that is at least 90% identical to SEQ. ID. No. 3; and   c. introducing the cell from step b into the same host.